MS-264 and MS-264 MRI contrast agents data

The Cambridge, Mass. company presented animal data showing improved magnetic resonance imaging of liver and breast tumors by the gadolinium-bearing compounds.

At the Conference of the Society of Magnetic Resonance in San Francisco, the company showed greater and more persistent uptake of MS-264 into liver compared to a gadolinium-based agent being developed by Schering AG. Of the injected dose, 85 percent concentrated in the liver (the value was 35 percent for the Schering agent), and boosted the MRI signal by 50 percent. Toxicology has shown the compound to be safe and well tolerated in doses 100 times higher than the anticipated human dose, the company said. Clinical trials of MS-264 are planned for later this year. ...